Cellectis R&D Day Highlights Pipeline Progress and Long-Term Value
Biotechnology company Cellectis hosted an R&D Day in New York, presenting full Phase 1 data for lasme-cel and outlining the Phase 2 strategy for B-ALL.
New York, NY – October 16, 2025 – Cellectis, a clinical-stage biotechnology company developing cell and gene therapies with its gene editing platform, held an R&D Day in New York City today. The event featured presentations by the company's leadership and key opinion leaders on the full Phase 1 dataset for lasme-cel (UCART22).
The company focused on the progress of lasme-cel, a product candidate for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The Phase 1 data presented offered detailed insights into the safety and efficacy of the therapy in patients who have not responded to prior treatments.
Cellectis leadership also outlined the pivotal Phase 2 trial design and commercial opportunity for lasme-cel. This phase is intended to further validate the therapy's potential and support its path toward broader clinical application. The company emphasized its long-term value drivers and its position in the gene editing therapy space.
The R&D Day was conducted in-person and via live webcast, providing an in-depth look at Cellectis' pipeline and strategic direction. A replay of the event is available on the Cellectis website.